HR Execs on the Move

Tenaya Therapeutics

www.tenayatherapeutics.com

 
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Joanna Auch
Senior Vice President of People and Culture Profile
Kathy Ivey
Director of Research Operations Profile

Similar Companies

Tasso

Tasso is changing the way that care is delivered with simple, virtually painless, clinical-grade diagnostic testing that can be done from home.

Brain TunnelGenix Technologies Corp

Brain TunnelGenix Technologies Corp is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tomtec Inc

Tomtec Inc is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vivacelle Bio

Welcome to Vivacelle Bio Inc.

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.